GenomOncology Launches Full Workflow for Genomic Cancer Testing
Forty percent of clinical labs say long-read whole-genome sequencing (WGS) is the most common genomic test they perform, yet only 12 percent have a system in place to create complete clinical reports. On July 30, GenomOncology, based in Cleveland, announced a new workflow that turns sequencing data into actionable clinical reports, reducing the typical four-step process down to just two. The system allows labs to use a single, integrated platform to automate their workflows and streamline operations.
The new system starts with the secondary analysis pipeline from PacBio. This pipeline takes raw sequencing data and converts it into aligned reads ready for analysis. Once that step is complete, GenomOncology's Pathology Workbench steps in to detect genetic variants, assess the strength of their clinical evidence, and prepare the findings into structured reports. Labs can select from a list of 20 pre-designed report templates focused on specific tumor types, such as breast, lung, and myeloid cancers. This ensures outputs comply with both clinical needs and billing standards.
By combining variant calling, quality assurance reviews, and report formatting into one automated system, the new workflow cuts the overall process by 60 percent. Validation tests using control and reference samples showed the system achieves 98 percent accuracy in identifying genetic changes, while cutting the time for reporting by 40 percent. This efficiency helps labs handle more cases without increasing workload.
Matthew Stachowiak, Vice President of Innovation at GenomOncology, called the new workflow a 'scalable path from instrument output to clinical report.' The system features a central dashboard that lets pathologists check coverage quality, phased variant data, and methylation patterns in real time. At the same time, reports are generated automatically in the background without the need for manual input, improving speed and accuracy.
Thanks to the modular design of the workflow, labs can create multiple reports from a single sequencing run to support different tumor types or diagnostic strategies. This flexibility eliminates the need to run separate tests for each clinical scenario, saving both time and costs. By simply adjusting analysis settings, laboratories can reuse up to 80 percent of the original sequencing data across multiple reports.
GenomOncology will showcase the system at the Cancer Genomics Consortium (CGC) Annual Meeting in Houston, running through August 5. Attendees will see firsthand how the workflow transforms PacBio's HiFi WGS data into standardized clinical reports. The tools available include real-time views of quality control metrics and variant annotations, enabling quick and accurate interpretation during the reporting process.
GenomOncology specializes in turning complex genomic data into actionable insights for cancer care. The company's AI-enhanced reporting solutions provide embedded decision-making tools that integrate smoothly into existing clinical workflows. This helps ensure accurate and timely decisions for patient treatment. More information is available at www.genomoncology.com.
For media inquiries, contact GenomOncology at marketing@genomoncology.com. The PacBio HiFi WGS pipeline mentioned in this release is intended for research use only and is not approved for diagnostic procedures.